<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04461899</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0002</org_study_id>
    <secondary_id>2020-A00118-31</secondary_id>
    <nct_id>NCT04461899</nct_id>
  </id_info>
  <brief_title>Changes in Serum antimüllerian Hormone Levels in Patients 3 and 12 Months After Endometrioma Sclerotherapy</brief_title>
  <acronym>ENDOPAL AMH</acronym>
  <official_title>Changes in Serum antimüllerian Hormone Levels in Patients 3 and 12 Months After Endometrioma Sclerotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometriosis affects 6-10% of women in childbearing age. It is a heterogeneous disease with
      three different forms: superficial endometriosis (peritoneal), ovarian endometrioma and deep
      pelvic endometriosis (subperitoneal).

      Surgical management of endometriomas is justified in cases of significant clinical symptoms
      (like pain), especially in cases of resistance to medical treatment. Currently, laparoscopic
      cystectomy surgery is the recommended technique to treat ovarian endometrioma. However, it is
      now well demonstrated that this surgery significantly reduces the ovarian reserve.

      Ethanol sclerotherapy is an alternative technique used to treat ovarian endometriomas.
      Several studies demonstrated the effectiveness and safety of this treatment, particularly in
      terms of preserving fertility. Regarding these reassuring data, many clinicians changed their
      practices and propose this technique as a first-line surgery.

      Ovarian reserve comprises two elements: size of the primordial follicle stock and quality of
      the ovocytes. Antimüllerian hormone (AMH) has been shown to be the best marker of fertility.

      The aim of this study is to observe changes in AMH levels after endometrioma sclerotherapy.
      This study is conducted in the Hospices Civils de Lyon, in 3 different sites.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AMH level</measure>
    <time_frame>3 months (+/-15 days) after endometrioma sclerotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AMH level</measure>
    <time_frame>12 months (+/-15 days) after endometrioma sclerotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMH level</measure>
    <time_frame>12 months after endometrioma sclerotherapy</time_frame>
    <description>AMH level 3 and 12 months after endometrioma sclerotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrioma recurrence</measure>
    <time_frame>3 months (+/-15 days) after endometrioma sclerotherapy</time_frame>
    <description>New endometrioma (≥ 2 cm) unilateral or bilateral, single or multiple</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrioma recurrence</measure>
    <time_frame>12 months (+/-15 days) after endometrioma sclerotherapy</time_frame>
    <description>New endometrioma (≥ 2 cm) unilateral or bilateral, single or multiple</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Endometriosis Ovary</condition>
  <arm_group>
    <arm_group_label>sclerotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>a sclerotherapy will be done in patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>additional blood test will be done 3 and 12 months after endometrioma sclerotherapy.</description>
    <arm_group_label>sclerotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient in childbearing age from 18 to 42 years.

          -  Patient with uni- or bilateral endometrioma(s) without clinical and ultrasound
             criteria for ovarian carcinoma.

          -  A sclerotherapy is programmed.

          -  Patient affiliated to a social security scheme.

          -  Patient who gave consent for this research.

        Exclusion Criteria:

          -  doubt about the endometriotic origin of the cyst

          -  suspect malignant ovarian disease.

          -  Pregnant or breastfeeding patient.

          -  Patient participating in other research with an exclusion period still in progress at
             the time of inclusion or those included in interventional research that interferes
             with the study protocol.

          -  Patient deprived of liberty by judicial or administrative decision.

          -  Patient (≥ 18 years old) under legal protection or unable to give consent.

          -  Patient does not speak French.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil DUBERNARD, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gil DUBERNARD, Pr</last_name>
    <phone>4 72 07 16 37</phone>
    <phone_ext>+33</phone_ext>
    <email>gil.dubernard@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie WAREMBOURG, Dr</last_name>
    <phone>4 72 07 19 36</phone>
    <phone_ext>+33</phone_ext>
    <email>sophie.warembourg@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno SALLE, Pr</last_name>
      <phone>4 72 12 94 12</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gil DUBERNARD, Pr</last_name>
      <phone>4 72 07 16 37</phone>
      <phone_ext>+33</phone_ext>
      <email>gil.dubernard@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François GOLFIER, Pr</last_name>
      <phone>4.78.86.41.79</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endometrioma</keyword>
  <keyword>sclerotherapy</keyword>
  <keyword>ovarian reserve</keyword>
  <keyword>antimüllerian hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

